Posterior drug delivery Dr Athmar Dhahir Habeeb PhD in Industrial Pharmacy and pharmaceutical formulations Delivery of drugs to the posterior eye is challenging owing to anatomical and physiological constrains ID: 928521
Download Presentation The PPT/PDF document "Posterior Drug delivery" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Posterior Drug delivery
Posterior
drug
delivery
Dr
Athmar
Dhahir
Habeeb
PhD in Industrial Pharmacy and pharmaceutical formulations
Slide2Delivery of drugs to the posterior eye is challenging, owing to anatomical and physiological constrains
of the
eye. There is an increasing need for managing rapidly progressing posterior eye diseases, such as age related macular degeneration, diabetic retinopathy, uveitis, macular oedema and retinitis pigmentosa. Drug delivery to the posterior segment of the eye is therefore compounded by the increasing number of new therapeutic entities (e.g. oligonucleotides, aptamers and antibodies) and the need for chronic therapy.
Anatomy of the posterior segment
Slide3Barriers to posterior drug delivery
Slide4The inner limiting membrane (ILM) and the BRB are the
main biological
barriers to drug transport from the vitreous to the retina. The ILM forms a border between the vitreous humour and the retina
and is the primary barrier to drug diffusion to the retina
The
BRB, which is composed of the endothelial cells of
retinal blood
vessels and the retinal pigmented epithelium (RPE),
forms the
secondary barrier to the transport of
lipophilic drugs
to
the inner
retinal cells.
Studies
have shown rapid clearance of
lipophilic molecules
administered into the vitreous by passive diffusion
via the
BRB.
Furthermore
, the efflux transporters in the
endothelium lead
to rapid elimination of molecules that are substrates for
this innate
active transport mechanism
Slide5Topical, systemic, intravitreal
and
periocular routes can be used to deliver pharmaceuticals to the posterior segment of the eye. The topical route is inefficient in delivering therapeutic concentrations of a drug to the posterior segment, owing to rapid drainage through the nasolacrimal ducts, low permeability of the corneal epithelium, systemic absorption and the blood–aqueous barrier.
Routes of drug delivery to the posterior eye
Slide6Conversely
the blood–retinal barrier (BRB) hinders the diffusion of systemically administered drugs to the posterior segment of the eye. Frequent systemic administration of high doses is also likely to exacerbate drug-related toxicities owing to nonspecific absorption.
Consequently, the ideal routes of drug delivery to the posterior segment are the intravitreal and the periocular routes
Slide7Slide8Intravitreal injection
provides
increased drug concentrations at the retina and minimizes systemic side effects. Drug molecules injected into the vitreous in the clinic are divided into two categories; high molecular weight proteins and small molecular weight molecules such as anti-inflammatory drugsThe two main routes by which a drug is eliminated from the vitreous humour are either via the anterior chamber or across the retinal surface
. The elimination and distribution kinetics are affected by the rate of drug diffusion through the vitreous and the geometry of the eye.
Intravitreal route
Slide9Larger molecules
are retained
in the vitreous for long periods (weeks); but molecules that are <500 Da and are in the form of a solution need frequent administration, owing to a limited retention half life of approximately 3 days. Drugs with large molecular weight and high water solubility, such as proteins, are eliminated by permeation through blood aqueous barriers to the anterior chamber followed by elimination through aqueous turnover and uveal blood flow. Hydrophobic drug molecules and small molecular weight drugs
are eliminated through posterior route by permeation through blood retinal barriers
Slide10schematic illustration of the main parts of the anterior and posterior segments, barriers to ophthalmic drug delivery and routes of drug elimination from the vitreous.
The location of
ophthalmic barriers
(encircled in red) are; I) the cornea and tear film; II) blood-retinal barriers; III) blood-aqueous barriers.
Routes
of elimination from the vitreous (encircled in blue) are; 1) venous blood flow after diffusing across the iris surface; 2) aqueous humour outflow; 3) diffusion into the anterior chamber (1, 2 and 3 are referred to diffusion through the blood-aqueous barriers); 4) diffusion through the blood–retinal
barrier
Slide11Intravitreal injection
can provide adequate drug concentrations in the posterior segment. Owing to the invasive nature of the injection, it is important to design drug formulations to maintain the therapeutic drug concentration over prolonged periods and minimize the number of injections
Frequent administration of drugs via this route can lead to retinal detachment, retinal haemorrhage, endophthalmitis and increased intraocular pressureNovel drug-delivery systems have been developed in the form of biodegradable or non-biodegradable implants, which can be placed long term in the vitreous
Slide12Biodegradable
and non-biodegradable Ocular implants provide a platform for the sustained release of molecules from either biodegradable or non-biodegradable polymeric matrices over several months to years. These implants are either injected into the vitreous or sutured onto the sclera for intravitreal or transscleral drug delivery.
Implants
Slide13Biodegradable implants do not require post-treatment removal, however
they
offer relatively less control over drug release compared to non-biodegradable implants it is very difficult to retrieve the implant when side effects start to show can cause more erratic drug-release profiles. Polymeric materials commonly used to fabricate biodegradable implants include poly(lactic-co-glycolic acid) (PLGA),
polycaprolactone
(PCL),
polyanhydride
and
poly(
ortho
ester) (POE).
Biodegradable implants
Slide14Non-biodegradable implants require invasive surgical removal,
better
control over the release of the drug compared to biodegradable ones over prolonged period of time Polymers commonly used for the fabrication of non-biodegradable implants are silicone, polyvinyl alcohol (PVA) and ethylene vinyl acetate (EVA)Non-biodegradable implants
Slide15Implants can be designed as either
a
reservoir or matrix system. Reservoir systems are noneroding devices that provide superior control of drug release by virtue of a specific physical rate control feature linked with the internal drug reservoir. This feature may be an opening in the device,
a porous
membrane or a coating through which
drug diffusion
is retarded.
It
is easier to achieve
zero-order drug
release kinetics using a reservoir system
as
there is only a single rate controlling variable
that may
impact drug delivery.
Slide16In
a
matrix system, drug is comixed with the rate controlling polymer. A matrix device can be engineered to produce zero-order drug release kinetics, for example, if the polymer is noneroding and the release is then governed by polymeric chain relaxation and the dissolution rate of the drug. However, in such a device, the drug
concentration must
be high enough such that, when erosion
occurs from
the matrix, it produces sufficient
fenestrated channels
in the device for aqueous diffusion media
to reach
the internally located drug particles.
In a
noneroding
matrix system, the strength or
resilience of
the device could be compromised as diffused
drug produces
a series of interconnected voids through
the device.
Slide17If the polymer in the matrix device is
bioerodible
then the device may exhibit more complex drug release kinetics due to the erosion factor of the polymer which may contribute independently to the drug dissolution or diffusion behaviourCurrently, two surgically implanted, non-biodegradable intravitreal implants (Vitrasert1 and Retisert1) are in clinical use. Vitrasert1 contains ganciclovir for the treatment of CMV retinitis for up to eight months and is the mainstay therapy for patients with CMV retinitisRetisert1, which contains fluocinolone
acetonide
, is used for the treatment of chronic non-infectious posterior uveitis. This reservoir system releases
fluocinolone
for up to 2.5 years
.
Iluvien
®
was developed to deliver a very low dose of
fluocinolone
acetonide
to the retina for up to 3 years as a treatment for diabetic macular
edema
Slide18Slide19Slide20I-
vationTM
is a novel technology that incorporates a titanium helical coil to increase the surface area of drug release. The coil is coated with triamcinolone acetonide (TA) and non-biodegradable polymers and is expected to release TA for at least two years. Currently, I-vationTM is in Phase I clinical trials in patients with diabetic macular oedema
Slide21Several new approaches for IVT implants have been investigated such as the use of refillable delivery systems and cell encapsulated technology (Chen 2015
).
Ciliary neurotrophic factor (CNTF) delivery through cell encapsulated technique has been investigated for the treatment of dry age related macular degeneration (AMD) and retinitis pigmentosa. The device is composed of sealed semipermeable membrane of polyethylene terephthalate surrounding human retinal pigment epitheliums cells (ARPE-19) genetically modified to secrete recombinant human CNTF. Microelectromechanical systems (MEMS) are intraocular DDS that can be refilled with drug solution for long term therapy. The device consists of refillable drug reservoir with flexible
canula
. The device would be implanted in the subconjunctival space and allow the
canula
to be directed into the vitreous or the anterior chamber
Slide22Slide23Biodegradable i
mplants
such as Ozurdex® (dexamethasone in poly(lactic-co-glycolic acid) PLGA) releases incorporated dexamethasone over four to six weeksNon-biodegradable, such as Vitrasert® (ganciclovir with polyvinyl alcohol (PVA) and ethylene vinyl acetate),
Retisert
®
(
fluocinolone
acetonide
with silicone and PVA),
Iluvien
®
(
fluocinolone
acetonide
with polyimide and PVA)
Slide24Periocular routes
Slide25The periocular route
of drug delivery enables the deposition
of molecules against the external surface of the sclera, thereby minimizing the risk of endophthalmitis and retinal damage associated with the intravitreal route of administration It is considered to be the least painful and the most efficient route of drug delivery to the posterior eyeBoth the subconjunctival and the
subtenon
routes are
widely used
in research into
transscleral
drug delivery
owing to
their proximity
to the sclera.
Slide26With
subconjunctival injection
, the formulation is placed beneath the conjunctival membrane that covers the sclera. This enables the drugs to bypass the conjunctiva– cornea barrier, giving direct access to the transscleral route. Subtenon injection involves the placement of a formulation between the sclera and Tenon’s capsule, an avascular membrane. As such, the contact time between the administered drug and the sclera is prolonged. Consequently, the subtenon route is considered to be one of the most promising routes for targeting the posterior segment of the eyeNevertheless, only minute concentrations of a drug administered via the
transscleral
route end up in the
vitreous.
This low bioavailability can be attributed to the loss of the drug from the periocular space, BRB, choroidal circulation and the binding of drugs to tissue proteins as well as efflux transporters.
Slide27Slide28Various preclinical studies have demonstrated the efficacy
of micro-
and nanoparticles in delivering drugs to the posterior ocular tissue via the periocular routes and the intravitreal route of administrationThe present evidence suggests polymeric micro- and nanoparticles to be of value in targeted and controlled gene delivery for posterior eye diseases. However, a few barriers have to be overcome before micro- and nanoparticles can be tested in clinical trials for posterior eye diseases. These include improvement in encapsulation efficacy
, control of particle size and drug release rate,
stability of
molecules during manufacturing and large-scale
manufacturing of
sterile preparations
Micro- and nanoparticles
Slide29Such systems use a delivery method to localize a
photosensitizing compound
in the target tissue followed by activation using a non-thermal laser light. Verteporfin (Visudyne1) is a clinically available light-activated drug used for the treatment of wet AMD. Verteporfin is activated 15 min after IV administration using a non-thermal red laser light. The activated drug causes the
occlusion of
neovascular
vessels;
Light-induced systems
Slide30Iontophoresis has been shown to increase the
transscleral
permeability of many drugs, including fluorescein, steroids, antibiotics, antivirals and macromolecules. Transscleral iontophoresis delivers high concentrations of the applied drug to the choroid and the retina with minimal side effectsAdverse effects of iontophoresis include epithelial oedema, a decrease in endothelial cells, inflammatory infiltration and burns, the extent of which depends on the site of application, current density and duration.Recently, several iontophoresis devices have been developed with better tolerability and ease of use. These include Ocuphor1, EyeGate1 and Visulex1. Further assessment of these types of device is needed to determine the optimal protocol and conditions for safe and efficient application of ocular iontophoresis.
Iontophoresis
Slide31Conclusion
Delivery
of drugs to the posterior eye is challenging, owing to anatomical and physiological constrains of the eye. Currently, the intravitreal route is widely used to deliver therapeutic entities to the retina. However, frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Various controlled delivery systems, such as biodegradable and non-biodegradable implants
, liposomes and nanoparticles, have been developed to overcome such adverse effects, with
some success.
The periocular route is a promising alternative, owing to the large surface area and the
relatively high
permeability of the sclera. Yet, the blood–retinal barrier and efflux transporters hamper the
transport of
therapeutic entities to the retina.
As
such, the efficient delivery of drugs to the posterior eye remains
a major
challenge facing the pharmaceutical scientist.